Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2009

View Archived Issues

GeoVax presents update on clinical trials of its HIV/AIDS vaccine

Sanofi submits supplemental application to FDA for A(H1N1) pandemic vaccine

Clinical Data collaborates with CombinatoRx for novel B-cell cancer therapy

Terminal complement inhibitor eculizumab reduces clinical thrombosis in PNH patients

AZD-0530 fails to meet primary endpoint in phase II trial in extensive-stage SCLC

ADH-1 shows potent antitumor activity in vitro and in vivo in combination with erlotinib

ABT-869 combined with carboplatin/paclitaxel shown to be safe in NSCLC

Histamine H1 antagonist bilastine is safe in healthy human volunteers

CB1R antagonist AM-6545 improves plasma lipid profile and glucose tolerance in obese mice

Saphris approved by FDA for schizophrenia and bipolar I disorder

FDA approves Embeda for moderate to severe chronic pain

Abbott expands Xience V trial into crossover dual antiplatelet therapy trial

AGI and Axcan terminate AGI-010 agreement

FDA approves Pharming's IND for Prodarsan in Cockayne syndrome

NCI reports antiproliferative effect for cancer drug GAP-107B8

Pacgen acquires Xphase Pharmaceuticals

Patients enrolled in phase II Oncophage cancer vaccine trial in glioma

OncoGenex expands clinical development of OGX-427 in bladder cancer

Allergan claims sphingosine 1-phosphate receptor ligands as analgesics

Novel gamma-secretase modulators in early development at EnVivo Pharmaceuticals

First launch for Onglyza in U.S.

Endacea describes adenosine A1 antagonists as diagnostic agents

Merck Sharpe & Dohme and Merck & Co. report PARP inhibitors for cancer treatment

Panacos synthesizes new series of anti-HIV agents

Merck & Co. reports discovery of Cav2.2 calcium channel blocker with in vivo analgesic activity